Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05486546 · ClinicalTrials.gov registry record · NA

Contoura With Phorcides Compared to Wavefront Optimized LASIK

A NA study of Myopia and Astigmatism, sponsored by Daniel Terveen.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
4
Study locations

NCT05486546 is a NA study of Myopia and Astigmatism that is actively recruiting participants, run by Daniel Terveen. The registered enrollment target is 120 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (55% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05486546, a NA study of Myopia and Astigmatism, is actively recruiting participants, sponsored by Daniel Terveen.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
4
Study locations

Study Summary

Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.

Conditions Studied

Interventions

  • PROCEDURE Contoura with Phorcides
  • DEVICE WaveLight Wavefront Optimized

Study Locations (4)

Montana

  • Vance Thompson Vison - Bozeman

Nebraska

  • Vance Thompson Vision - Omaha

North Dakota

  • Vance Thompson Vision - Fargo

South Dakota

  • Vance Thompson Vision - Sioux Falls

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2022-08-15
Est. Completion 2023-12-01
Phase NA

Sponsor

Daniel Terveen

1 total trials

What the Registry Record Tells You About NCT05486546

The ClinicalTrials.gov registry entry for NCT05486546 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (55% lower). The listed sponsor is Daniel Terveen, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Contoura with Phorcides is the first listed.

NCT05486546 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Montana, Nebraska, North Dakota.

Frequently Asked Questions

What is clinical trial NCT05486546 about?

NCT05486546 is a clinical study titled "Contoura With Phorcides Compared to Wavefront Optimized LASIK". Comparing post-operative visual acuity and patient reported satisfaction between Contoura with Phorcides and WaveLight Wavefront Optimized.

What is the current status of trial NCT05486546?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-08-15. Estimated completion is 2023-12-01.

What conditions does trial NCT05486546 study?

This clinical trial studies the following conditions: Myopia, Astigmatism.

What interventions are being tested in trial NCT05486546?

The interventions under investigation include: Contoura with Phorcides (PROCEDURE), WaveLight Wavefront Optimized (DEVICE).

Who is sponsoring clinical trial NCT05486546?

This trial is sponsored by Daniel Terveen, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05486546 being conducted?

This trial has 4 study locations across Montana, Nebraska, North Dakota, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.